-+ 0.00%
-+ 0.00%
-+ 0.00%

AnaptysBio Plans To Complete Spin-Off Of Its Biopharma Portfolio Into Standalone Public Entity In Q2; New Entity To Be Named First Tracks Biotherapeutics, List On Nasdaq;

Benzinga·03/03/2026 21:24:33
Listen to the news

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec. 31, 2025.

  • Intention to separate biopharma operations from substantial royalty assets on track for Q2 2026, potentially as early as late-April
    • Designed to unlock potential value by creating two independent, publicly traded companies with different business objectives and opportunities
  • The royalty management company will initially retain the name AnaptysBio (Nasdaq: ANAB) and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders
    • While specific decisions regarding board composition, leadership and financial operations will be disclosed at a later time, Daniel Faga is anticipated to be the initial CEO
  • First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX) (formerly referred to as Biopharma Co), will be a public company focused on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases, including ANB033, rosnilimab and ANB101